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Residual MHC Class II Expression
on Mature Dendritic Cells and Activated
B Cells in RFX5-Deficient Mice
and can thus influence the efficiency of T cell activation
and the immune response that is elicited (Janeway et
al., 1984). Conversely, the lack of MHC-II expression
results in severe immunodeficiency (Klein et al., 1993;
Cardell et al., 1994; Grusby and Glimcher, 1995).
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Much of what is known about the molecular mecha-University of Cologne
nisms controlling expression of MHC-II genes has comeWeyertal 121
from the study of patients with a rare hereditary immuno-D-50931 Cologne
deficiency disease called MHC-II deficiency, sometimesGermany
also referred to as the bare lymphocyte syndrome²Louis Jeantet Laboratory of Molecular Genetics
(Glimcher and Kara, 1992; Reith et al., 1998). This defi-Department of Genetics and Microbiology
ciency in MHC-II expression results from defects inUniversity of Geneva Medical School
trans-acting regulatory genes required for transcrip-CMU, 9 Avenue de Champel
tional activation of MHC-II promoters (Mach et al., 1996;CH-1211 Geneva 4
Reith et al., 1998). The disease is genetically heteroge-Switzerland
neous: patients have been classified into four different
genetic complementation groups (A, B, C, and D) (Beni-
chou and Strominger, 1991; Seidl et al., 1992) reflectingSummary
the existence of four distinct regulatory genes. Three of
these regulatory genes, CIITA, RFX5, and RFXAP, havePatients with major histocompatibility complex class
been isolated (Steimle et al., 1993, 1995; Durand et al.,II (MHC-II) deficiency are known to carry mutations in
1997). CIITA, the gene mutated in group A, encodeseither the RFX complex or the trans-activator CIITA.
a non±DNA-binding trans-activator that functions as aWhile the pivotal role of CIITA for MHC-II gene tran-
molecular switch controlling the cell type specificity,scription is supported by the essential absence of
inducibility, and level of MHC-II expression (Steimle etMHC-II molecules in CIITA-deficient mice, we demon-
al., 1993, 1994; Muhlethaler-Mottet et al., 1997). RFX5strate here that RFX52/2 mice retain expression of
and RFXAP, the genes mutated in groups C and D re-MHC-II in thymic medulla, mature dendritic cells, and
spectively, encode two subunits of RFX, a multimericactivated B cells. Nevertheless, RFX52/2 mice develop
transcription factor complex (Reith et al., 1988; Steimlea severe immunodeficiency due to the lack of MHC-II
et al., 1995; Durand et al., 1997) that binds to a specificin thymic cortex, failure of positive selection of CD41
cis-acting sequence (the X box) present in thepromotersT cells, and absence of MHC-II on resting B cells and
of all MHC-II genes (Benoist and Mathis, 1990). Thoughresident or IFNg-activated macrophages. This differ-
RFX is expressed ubiquitously (W. R., unpublished data),ential requirement for CIITA and RFX5 in subsets of
its only known function is to regulate transcriptionalantigen-presenting cells may be specific for the mouse;
activity at MHC-II promoters. It participates in coopera-it may, however, also exist in humans without having
tive protein±protein interactions that are required forbeen noticed so far.
stable and specific recruitment of other DNA-binding
proteins to the promoter (Reith et al., 1994a, 1994b;
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Moreno et al., 1995). In addition, its RFX5 subunit has
recently beenshown to interact in vitro with CIITA(Scholl
Major histocompatibility complex class II (MHC-II) anti- et al., 1997).
gens are cell surface molecules that play a pivotal role
Despite its genetic heterogeneity,MHC-II deficiency is
in the immune response. They present antigenic pep-
believed to be phenotypically homogeneous. Although
tides to the receptor of CD41 T lymphocytes, shape
weak residual expression of MHC-II molecules on cer-
the T cell repertoire by directing positive and negative tain cell types has been observed in several patients,
selection events in the thymus, and contribute to activa- no clear pattern of residual expression has been found
tion of the antigen-presenting cells (APC) on which they to be typical of a given complementation group (Klein
are expressed. Consequently, expression of MHC-II et al., 1993). This phenotypic homogeneity has also been
molecules is tightly regulated and largely restricted to observed at the level of cell lines established from pa-
specialized cell types including thymic epithelial cells, tients belonging to the four complementation groups.
professional APC such as macrophages, dendritic cells With few exceptions, these cell lines have the same
(DC) and B cells, and cells exposed to a variety of stimuli phenotype: namely, an essentially complete absence of
including immune regulators such as interferon-g (IFNg) constitutive or IFNg-inducible MHC-II expression. This
(Benoist and Mathis, 1990; Glimcher and Kara, 1992). lack of expression affects all three human MHC-II iso-
The level of MHC expression on professional APC can types: human leukocyte antigen DR (HLA-DR), HLA-DP,
determine their competence for antigen presentation, and HLA-DQ (de Preval et al., 1988; Steimle et al., 1993,
1995; Durand et al., 1997). Expression of the genes en-
coding the nonclassic HLA-DM molecule and the MHC-³To whom correspondence should be addressed (e-mail: foerster@
II±associated invariant chain (Ii) is also affected (Noceragenetik.uni-koeln.de and walter.reith@medecine.unige.ch).
§These authors contributed equally to this work. et al., 1993; Chang and Flavell, 1995; Kern et al., 1995).
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The lack of obvious phenotypic heterogeneity among and Schweighoffer, 1995; Jameson et al., 1995). That
insufficient expression of MHC-II in the thymus of Ab2/2patients and cell lines of the different complementation
groups has been interpreted to indicate that in humans, and CIITA2/2 mice results in a severe reduction of CD41
T cells is consistent with this notion (Cosgrove et al.,the regulatory factors CIITA, RFX5, and RFXAP all are
essential and highly specific for MHC-II expression. This 1991; Chang et al., 1996). In contrast, patients with MHC-
II deficiency exhibit only mildly reduced levels of CD41view has been corroborated by a nearly complete ab-
sence of MHC-II expression in mice deficient for CIITA T cells in the periphery (Klein et al., 1993). We therefore
sought to determine the severity of the CD41 T cell(Chang et al., 1996). Here, we present the establishment
and analysis of a mouse line harboring a mutation in the deficiency in RFX5-deficient mice by examining posi-
RFX5 gene. tive selection of CD4 single-positive (SP) thymocytes
(Figure 2A) and the peripheral CD41 T cell compartment
(Figure 2B).Results
Thymocytes from RFX52/2, RFX51/2, and Ab2/2 con-
trol mice were isolated and analyzed by fluorescence-Generation of RFX52/2 Mice
activated cell sorting (FACS) (Figure 2A). Whereas weThe targeting vector was constructed such that a loxP-
found a normal percentage of CD4 SP thymocytes inflanked neomycin-resistance (neor ) gene and a third
the heterozygous controls (Figure 2A, left, 7.6%), thereloxP site were inserted into introns situated upstream
was a drastic reduction of CD4 SP thymocytes inand downstream, respectively, of the region of RFX5
RFX52/2 mice (Figure 2A, middle, 1.4%). This reductionencoding the DNA-binding domain (Figure 1A) (Steimle
is as pronounced as that seen in the Ab2/2 mice (Figureet al., 1995). To allow negative selection against random
2A, right, 2.1%, and Cosgrove et al., 1991).integrants, the herpes simplex virus-1 thymidine kinase
The perturbed positive selection in the thymus is also(tk) gene was cloned downstream of the long arm of
reflected in the periphery of RFX5-deficient mice. Al-homology (Figure 1A). The targeting vector was linear-
though heterozygous controls show a normal represen-ized at the 59 end of the short arm of homology and
tation of CD41 T cells in mesenteric lymph node (LN)transfected into E14.1 embryonic stem cells by electro-
cells (Figure 2B, 34.9%), there is a profound deficiencyporation. Transfectants were selected with G418 and
of peripheral CD41 T cells in RFX52/2 mice (Figure 2B,gancyclovir, and double-resistant clones were screened
3.1%). As observed for thymocytes, the reduction inby polymerase chain reaction (PCR). Homologous re-
peripheral CD41 T cells is similar to that found in Ab2/2combination was confirmed by genomic Southern blot
mice (Figure 2B, 2.1%).analysis (Figure 1B, XbaI digest).
Of five PCR-positive homologous recombinants, two
harbored a cointegration of the third loxP site (Figure Functional Immunodeficiency in RFX52/2 Mice
To assess the function of the few remaining CD41 T1B, HindIII digest). These two clones (23 and 50) were
injected into C57Bl/6 blastocysts to generate chimeric cells in the RFX5 knockout and to determine whether B
cells have an intrinsic defect resulting from the RFX5mice (Torres and KuÈ hn, 1997). The chimeras were
crossed to the ªdeleterº strain expressing Cre recombi- deficiency, we determined the normal serum immuno-
globulin levels in RFX52/2 mice and tested the responsenase in the germline (Schwenk et al., 1995), and offspring
from this cross were screened for germline deletion at of these mice to antigenic stimulation (Figure 2C). The
basal levels and distribution of immunoglobulin isotypesthe RFX5 locus by Southern blotting (Figures 1A and
1C). Homozygous RFX52/2 mice were obtained from in the absence of deliberate immunization were unal-
tered in RFX52/2 mice compared to heterozygous andclone 50 by intercrossing heterozygous mice (Figure
1D). RFX52/2 mice are healthy and reproduce normally Ab2/2 controls (data not shown). RFX52/2 and control
mice were then immunized with the T cell±dependentwhen housed in a specific pathogen±free animal facility.
RFX51/2 mice were indistinguishable from wild-type (TD) antigen 4-hydroxy-3-nitrophenylacetyl coupled to
chicken g-globin (NP-CG) or with the T cell±independentmice and were used as controls throughout the analysis.
Cre-mediated deletion between the outer loxP sites (TI) type 2 antigen NP-Ficoll (Figure 2C). RFX52/2 mice
failed to produce measurable NP-specific IgM followingresults in excision of exons 4±7 from the RFX5 gene.
This leads to splicing of exon 3 to exon 8 and generates immunization with NP-CG (Figure 2C, top), similar to the
result observed with Ab2/2 mice. Compared to RFX51/2a frameshift mutation followed 2 amino acids further
downstream by a premature stop codon, as demon- controls, RFX52/2 mice produced 100- to 1000-fold re-
duced levels of NP-specific IgG1 in the course of thestrated by reverse transcriptase (RT)±PCR and sequence
analysis of the amplification products (Figure 1E). At secondary response (Figure 2C, top). This low titer is
nevertheless above the background level of IgG1 foundbest, therefore, only a severely truncated protein con-
sisting of the first 77 amino acids of RFX5 can be made in Ab2/2 mice. In contrast to the TD response, RFX52/2
mice responded to the TI antigen NP-Ficoll with normalin the mutant mice. This mutation is similar to the
C-terminal deletions identified in patients with MHC-II titers of IgM and IgG3 (Figure 2C, bottom), indicating
that there is no intrinsic defect in RFX5-deficient B cellsdeficiency (SJO [Steimle et al., 1995] and TF [Villard et
al., 1997]). The latter C-terminally truncated versions of for becoming immunoglobulin-producing plasma cells.
RFX52/2 mice thus exhibit an immune deficiency that isRFX5 have been shown to be completely nonfunctional
(Steimle et al., 1995, and W. R., unpublished data). very similar to that of MHC-II±deficient patients.
MHC-II Expression on DC, B Cells, andCD4 T Cell Development Is Severely
Impaired in RFX52/2 Mice Macrophages of RFX52/2 Mice
To test for constitutive expression of MHC-II moleculesMaturation of CD41 T cells requires the presence of
MHC-II molecules on thymic epithelial cells (Fowlkes in RFX52/2 mice, we analyzed frozen tissue sections
Residual MHC II Expression in RFX5-Deficient Mice
145
Figure 1. Construction of Targeting Vector and Generation of RFX52/2 Mice
(A) Genomic RFX5 locus and targeting construct (top) and targeted locus and deleted allele (bottom). Homologous recombination introduces
a loxP-flanked neor gene 59 of exon 4 and a third loxP site downstream of exon 7. Cre-mediated recombination deletes the neor cassette and
the exons encoding the DNA-binding domain (DBD). Coding exons are indicated as filled boxes, 59 and 39 untranslated exons as shaded
boxes, loxP sites as filled triangles, and selectable genes as open arrows. Small arrows at the 59 end of the targeted locus represent PCR
primers used to screen for homologous recombinants (C5 and PGKNEO1). The 59 external probe (59 MRFX5 probe) used for Southern blot
analysis is shown at the bottom. X, XbaI; H, HindIII.
(B) Southern analysis of homologous ES cell recombinants. XbaI digestion of genomic DNA yields restriction fragments of 9.7 kb (wt) and 5.2
kb (targeted) when hybridized with the 59 external probe (left). In the targeted clones, cointegration of the third loxP site introduces a HindIII
restriction site, resulting in replacement of an 11 kb fragment by a 3.4 kb fragment when hybridized with a neo probe (right).
(C) Southern analysis of germline-transmitted offspring of RFX5 chimeras crossed to the ªdeleterº strain. In case of Cre-mediated recombination
in the germline, the 5.2 kb XbaI-fragment of the targeted locus is replaced by a 8.2 kb fragment in the deleted allele.
(D) PCR analysis of wild-type, heterozygous, and homozygous littermates of RFX5 heterozygous intercrosses. Tail DNA was tested with
primers N4, N8, and INT1. Wild-type and deleted alleles are indicated by 250 bp and 500 bp bands, respectively.
(E) RT-PCR analysis of RFX5 mRNA in B cells and mesenteric LN cells from RFX51/2 and RFX52/2 mice. Lanes 1, without RT; lanes 2, with RT;
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the thymic medulla of CIITA2/2 mice (Figures 3f and 3g
and Chang et al., 1996). In the spleen, MHC-II expression
was not detectable on follicular B cells (Figure 3j). The
lack of MHC-II on the surface of RFX52/2 B cells was
also confirmed by FACS analysis (data not shown). In
contrast, we observed significant staining for MHC-II in
the central T cell areas of the splenic follicles in RFX52/2
mice (Figure 3j). Staining of consecutive sections with
antibodies specific for MHC-II, CD11c, and DEC-205
(Jiang et al., 1995) strongly suggests that these MHC-II1
cells are CD11c1DEC-2051 mature DC (data not shown).
The same colocalization of residual MHC-II expression
and staining for DEC-205 was also found in sections
from LN of RFX52/2 mice (data not shown). Staining for
both MHC-II and DEC-205 was always restricted to the
paracortical areas within the LN.
The residual MHC-II expression in the thymus and
spleen of RFX52/2 mice was observed with two different
I-Abb±specific monoclonal antibodies: M5/114 (Figure 3)
and 25±9±17 (data not shown). The immunohistologic
staining intensity was particularly strong with M5/114
(compare Figures 3e and 3f and Figures 3i and 3j, and
data not shown). When M5/114 was used to detect func-
tional cell surface MHC-II molecules in FACS experi-
ments, staining of RFX52/2 cells was less bright than
that of wild-type cells (see below). The reason for the
strong staining with M5/114 in tissue sections remains
unclear. Perhaps it represents staining of intracellular or
misfolded MHC-II molecules, such as excess Ab chains,
which may be overproduced in RFX5 mutant cells (see
below), or MHC-II molecules that have not been cor-
rectly loaded with peptides as a consequence of a re-
duction in Ii and H-2M expression (see below). In
agreement with this hypothesis, M5/114 has been
shown to bind to abnormally folded I-Ab chains (Elliott
et al., 1994). Using this antibody, we also occasionally
detected a weak residual expression of I-Abb in the T
cell areas of the splenic white pulp of CIITA2/2 mice
(Figure 3k) (see also Discussion).Figure 2. T Cell Development and Function in RFX52/2 Mice
Kupffer cells in the liver, which belong to the mac-Representative FACS analyses of (A) thymus and (B) mesenteric LN
rophage lineage, are devoid of detectable MHC-II mol-of RFX52/2, RFX51/2 and Ab2/2 mice stained for surface expression
ecules inRFX52/2 mice, whereas these cells are MHC-II1of CD4 versus CD8. Percentages of gated cells are indicated. (C)
Immune response of RFX52/2 and control mice to the TD antigen in the heterozygous mice (Figures 3j and 3k). Similarly,
NP-CG or the TI (type 2) antigen NP-Ficoll. IgM and IgG1 antibody F4/801 and Mac-11 splenic macrophages of RFX52/2
responses weremeasured at0 and11 days after primary (18) immuni- mice are also MHC-II2 by FACS analysis (data not
zation with NP-CG, and the recall IgG1 response was assessed 6
shown). On the other hand, we occasionally detectedand 25 days after secondary (28) immunization (top). NP-specific Igl
individual MHC-II1 cells near the walls of blood vesselsand IgG3 antibodies were measured at 0 and 11 days after NP-
in the liver (Figure 3n). The nature of these cells remainsFicoll immunization (bottom). For comparison, serum titers obtained
from RFX51/2 (open triangles), RFX52/2 (filled circles), and Ab2/2 to be identified.
(open squares) mice are shown.
RFX5 Independent Expression of MHC-II
in Mature DCof thymus (Figures 3a±3h), spleen (Figures 3i±3l), liver
(Figures 3m±3p), and LN (data not shown) by immuno- To investigate whether the MHC-II1 cells in RFX52/2
mice are indeed DC, we purified CD11c1 DC from thehistochemistry. Tissue sections from RFX51/2 and Ab2/2
mice were used as positive and negative controls. In spleen of Aa2/2, CIITA2/2, RFX52/2, and RFX51/2 mice
and assessed the surface expression of MHC-II (Figureaddition, sections from CIITA2/2 mice were included for
comparison. In the thymus of RFX52/2 mice, the cortex 4A). In this particular experiment, Aa2/2 mice (Kontgen
et al., 1993) were used as negative controls to compen-was almost completely MHC-II2; only a few scattered
individual MHC-II1 cells were visible. In contrast, the sate for potential background staining caused by free
I-Ab chains. In contrast to the histological analysis (seethymic medulla stained strongly and homogenously for
MHC-II. This strong staining was clearly distinct from above), the two MHC-II antibodies 25±9±17 and M5/
114 stained DC with the same but comparatively lowthe patchy appearance of MHC-II±expressing cells in
Residual MHC II Expression in RFX5-Deficient Mice
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Figure 3. MHC-II Expression in Thymus, Spleen, and Liver
(a±h) Adjacent thymic sections of RFX51/2 (a and e), RFX52/2 (b and f), CIITA2/2 (c and g), and Ab2/2 (d and h) mice were stained with
hematoxylin/eosin to resolve the darker cortex from the lighter medulla (a±d) or with M5/114 (red) for MHC-II molecules and counterstained
with hematoxylin (blue) (e±h). M, thymic medulla; C, thymic cortex.
(i±l) Double staining for B220 (blue) and MHC-II (red) on splenic sections of RFX51/2 (i), RFX52/2 (j), CIITA2/2 (k), and Ab2/2 (l) mice. RP, splenic
red pulp; B, B cell mantle of the splenic follicle; T, central T cell area.
(m±p) MHC-II staining on Kupffer cells in the liver of RFX51/2 (m), RFX52/2 (n), CIITA2/2 (o), and Ab2/2 (p) mice.
intensity in RFX52/2 mice (Figure 4A, compare a±d and precursors differentiate in vitro along the DC lineage
(Inaba et al., 1992; Scheicher et al., 1992). Our findinge±h). This further indicates that the strong staining ob-
that the remaining MHC-II1 cells in RFX52/2 mice areserved with the M5/114 monoclonal antibody in histol-
CD11c1 DC was further corroborated by our identifica-ogy is due to intracellular staining. On the other hand,
tion of a minor yet distinct subpopulation of CD11c1it is clear that a substantial fraction of DC (13%±17%)
MHC-II1 DC in GM-CSF±supplemented BM cultures ofin the RFX52/2 mice retain surface expression of MHC-
RFX52/2 mice (Figure 4B). Although they were few com-II, as opposed to Aa2/2 and CIITA2/2 mice. Despite the
pared to the wild type (Figure 4B, 1.2% vs. 32%, respec-presence of this MHC-II1 DC population, it remains evi-
tively), these cells were absent in DC differentiated fromdent that RFX5 is an important MHC-II regulatory factor
Ab2/2 BM precursors (Figure 4B, 0.2%).The low percent-in DC since (1) only few of the MHC-II1 DC present in
age of MHC-II1 DC in BM cultures from RFX52/2 micethe RFX52/2 mice expressed wild-type levels of MHC-II
may be attributed to the generation of predominantlyand (2) the majorityof RFX5-deficient DC did not express
immature DC under these conditions (Inaba et al., 1992;surface MHC-II (Figure 4A, c and g). This is in contrast
Scheicher et al., 1992). This finding indicates that onlyto heterozygous controls, where essentially all CD11c1
mature DC can bypass the RFX5 defect and expressDC were MHC-II1 (Figure 4A, d and h). There was no
MHC-II molecules.clear correlation between the presence or absence of
MHC-II on RFX5-deficient DC and a ªlymphoidº or ªmy-
eloidº origin of the DC, as distinguished by surface ex- IFNg-Induced MHC-II Expression Is Abolished
in Peritoneal Macrophagespression of CD8 (Steinman et al., 1997) (data not shown).
As an additional point, a direct comparison of the histo- In macrophages, expression of MHC-II genes can be
induced with IFNg (Boehm et al., 1997). To determinegrams obtained from Aa2/2 and CIITA2/2 mice reveals
a possible weak residual surface expression of MHC-II whether this inducible MHC-II expression requires RFX5,
resident peritoneal macrophages were isolated fromon CIITA2/2 DC. It remains to be verified whether this
expression level is significantly above background. RFX52/2 mice and treated with IFNg in vitro. FACS analy-
sis revealed that MHC-II expression was not up-regu-In the presence of granulocyte-macrophage colony-
stimulating factor (GM-CSF), mouse bone marrow (BM) lated by IFNg on the RFX5-deficient macrophages, while
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plus IL-4 are shown in Figure 5B. Similar results were
obtained with either LPS alone or IL-4 alone (data not
shown). In contrast to expression levels on RFX51/2
control cells, MHC-II surface expression was essentially
undetectable on unstimulated RFX52/2 and CIITA2/2 B
cells. However, RFX52/2 B cells, in contrast to CIITA2/2
B cells, do express MHC-II following stimulation with
LPS plus IL-4. The staining intensity of these cells was
approximately 10-fold lower than that of wild-type B
cells. This reduced induction of MHC-II expression is
not due to a general unresponsiveness of the RFX52/2
B cells to activation signals, since up-regulation of the
costimulatory molecule B7.2 was normal (Figure 5B).
A comparison among the FACS profiles of Ab2/2,
CIITA2/2, and RFX52/2 B cells grown in unsupplemented
medium reveals two subtle differences. First, the whole
unstimulated RFX52/2 B cell population stains slightly
more brightly, on average, than the Ab2/2 or CIITA2/2
cells. Second, the RFX52/2 cells contain a small subpop-
ulation that already expresses high levels of MHC-II in
the absence of in vitro stimulation. While the first obser-
vation might be due to nonspecific activation during cell
culture, we attribute the presence of the few strongly
MHC-II1 RFX52/2 B cells to activation in vivo prior to
preparation and culture of the cells.
Effect of the RFX5 Mutation on MHC-II, Ii,
and H-2M mRNA Levels
MHC-II expression was monitored at the mRNA level by
RNase protection, using probes specific for I-Ab, I-Aa,
and I-Eb (Figure 6, top, and Table 1). Expression of I-Ea
mRNA was not assayed because the RFX52/2 mutation
was on a mixed Sv129/C57Bl/6 background, in which
there is a natural deletion of the I-Ea locus. RNAs pre-
pared from mesenteric LN, spleen, different sources of
enriched DC, B cells, or macrophages were analyzed
(Figure 6).
MHC-II mRNA levels were undetectable or severely
Figure 4. MHC-II Expression on DC reduced in the RFX5-deficient animals in all cell types.
(A) FACS analysis of MHC-II expression on MACS-enriched CD11c1 Only splenic DC retained MHC-II mRNA levels that were
DC from Aa2/2, CIITA2/2, RFX52/2, and RFX51/2 mice. Surface stain- sufficiently high to account for the residual surface ex-
ing of MHC-II molecules was performed with two different antibod-
pression detected in these cells. This was evident bothies, 25±9±17 and M5/114. Histograms show the level of MHC-II
in the DC-enriched low-density fraction prepared fromexpression on CD11c1 DC; percentages of MHC-II1 cells within the
spleen and in the sorted CD11c1MHC-II1 DC. The levelsCD11c1 population are indicated.
(B) FACS analysis of in vitro BM-derived DC from RFX51/2, RFX52/2, of I-Ab, I-Eb, and I-Aa mRNAs present in the RFX52/2
and Ab2/2 mice. Percentages indicate the relative number of DC samples were estimated to represent, respectively,
CD11c1MHC-II1 cells. 67%, 30%, and 22% of wild type in the DC-enriched
splenic fraction, and 20%, 80% and 60% of wild type
in the purified CD11c1MHC-II1 DC (Table 1). The ab-
induction was normal in the control macrophages (Fig- sence of significant amounts of MHC-II mRNAs in
ure 5A). The lack of MHC-II induction in the RFX52/2 CD11c1 BM-derived DC further indicates that predomi-
macrophages is not due to a general defect in the IFNg nantly immature DC incapable of bypassing the RFX5
signaling pathway (Boehm et al., 1997), because expres- defect were generated in these cultures. Resting B2201
sion of MHC-I was up-regulated normally (Figure 5A). B cells enriched from the spleen of RFX52/2 mice ex-
pressed significant levels of I-Ab mRNA (Table 1, up to
40% of the wild type), but not I-Aa mRNA, which en-Induction of MHC-II Expression
on Activated B Cells In Vitro codes the corresponding partner required to form a
functional MHC-II heterodimer. Finally, resident perito-Resting splenic B cells in RFX52/2 mice lack constitutive
MHC-II expression (Figure 3j and data not shown). It neal macrophages from RFX52/2 mice did not express
significant amounts of any MHC-II isotype.was of interest to see whether these cells could be
induced to express MHC-II following in vitro activation In most cell types, the deficiency in RFX5 seems to
compromise the expression of I-Aa and I-Eb to a greaterwith lipopolysaccharide (LPS) and/or interleukin-4 (IL-4)
(Noelle et al., 1984). The results for stimulation with LPS extent than that of I-Ab. This was particularly evident in
Residual MHC II Expression in RFX5-Deficient Mice
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Figure 5. MHC-II Expression on IFNg-Activated Peritoneal Macrophages and Activated B Cells
(A) Peritoneal macrophages of RFX51/2 and RFX52/2 mice were cultured for 2 days in the presence or absence of IFNg. Induction of MHC-II
and MHC-I expression was determined by FACS. Histograms are plotted as overlays of the medium control (gray line) and cells grown in
medium supplemented with IFNg (black line).
(B) Splenocytes were prepared from Ab2/2, CIITA2/2, RFX52/2, and RFX51/2 mice and cultured in the presence or absence of LPS and IL-4.
After 2 days, expression of MHC-II and B7.2 (CD86) was determined by FACS analysis of B2201 B cells. Histograms show the relative staining
intensity of the medium control (gray line) and cells stimulated with LPS plus IL-4 (black line).
resting B cells, total LN cells, and the DC-enriched CD41 TD immune responses. However, RFX52/2 mice
splenic cell fraction. However, in purified and activated show a number of characteristics that have not been
CD11c1MHC-II1 DC, it was I-Ab mRNA that was most observed either in the patients or in CIITA2/2 mice
strongly reduced. This differential control of different (Chang et al., 1996).These novel features reveal an unex-
MHC-II genes has not been observed in patient cell lines pected complexity in the regulatory mechanisms con-
harboring a mutation in the RFX5 gene (Steimle et al., trolling expression of MHC-II genes in certain cell types
1995). in vivo. In particular, the mice provide strong evidence
In humans, RFX5 is required not only for expression for an RFX5±independent pathway for MHC-II expres-
of the classic MHC-II genes but also for the invariant (Ii) sion in key cellular compartments of the immune sys-
and HLA-DM genes, which are coregulated with MHC- tem, namely thymic medulla, mature DC, and activated
II genes and encode accessory proteins required for B cells.
antigen presentation (reviewed by Cresswell, 1996). In
cell lines deficient in RFX5, expression of Ii is reduced
Impaired CD41 T Cell Development and(W. R., unpublished data), and the DM genes remain
Immunodeficiency in RFX52/2 Micesilent (Kern et al., 1995).We performed RNase protection
With the exception of a few scattered cells, the thymicexperiments to evaluate the effect of the RFX5 mutation
cortex was found to be devoid of MHC-II expression. Inon expression of the murine Ii and H-2M genes (Figure
contrast, thymic medulla stained strongly and homoge-6, bottom, and Table 1). The results show that Ii and
neously for MHC-II (Figure 3). It is not clear whether aH-2M mRNA levels were decreased but not absent in
similar pattern of residual thymic MHC-II expression alsoRFX52/2 mice. As observed for the classic MHC-II
exists in humans lacking RFX5 since only two patientsisotypes, the extent to which the mRNA levels are re-
(TF and KD) have been analyzed for MHC-II expressionduced depends on the gene examined: the Ii and H-2Ma
in the thymus (Schuurman et al., 1985). No thymic MHC-genes were affected less strongly than theH-2Mb genes
II expression was detected in patient TF, who was later(Table 1).
found to have disrupted RFX5 genes (Villard et al., 1997).
On the other hand, patient KD exhibited a pattern similarDiscussion
to that of the RFX52/2 mice. However, the genetic defect
in this patient has not been elucidated. Although theRFX52/2 mice exhibit many of the features typical of
phenotype of patient TF is difficult to reconcile with thethe human disease, including a severely disturbed pat-
tern of MHC-II expression and a profound deficiency in present data, these findings raise the possibility that
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Figure 6. Expression of MHC-II, Ii, and H-2M
mRNAs
mRNA levels for the Ab, Eb, and Aa genes
(top) and the Ii, H-2Ma, H-2Mb1, and H-2Mb2
genes (bottom) were analyzed by RNase pro-
tection. GAPDH (G) mRNA was used as in-
ternal control. RNAs were from (1) a total
GM-CSF supplemented BM culture; (2) FACS-
sorted CD11c1 BM-derived DC; (3) low-den-
sity spleen cells enriched for DC (z10% DC);
(4) MACS-enriched B2201 B cells; (5) total
mesenteric LN cells; (6) splenic CD11c1MHC-
II1 DC, sorted after depletion of contaminat-
ing macrophages by plastic adherence and;
(7) FACS-sorted F4/801 peritoneal macro-
phages. Equal amounts of RNA from RFX51/2
and RFX52/2 mice were analyzed. Positions
of protected bands and sizes in nucleotides
of reference fragments (lanes M) are indi-
cated.
residual thymic MHC-II expression may well occur in cells appear to be incapable of providing T cell help in
TD immune responses. While the response of RFX52/2certain patients with MHC-II deficiency but has gone
unnoticed because of the limited data available. Alterna- mice to the TD antigen NP-CG is 100- to 1000-fold re-
duced compared to wild-type levels, they respond nor-tively, the dependence of thymic MHC-II expression on
RFX5 may differ between mice and humans. mally to the TI type 2 antigen NP-Ficoll. Thus, there are
no functional abnormalities in the B cell population itselfPositive selection of CD4 SP thymocytes is mediated
by MHC-II expression on thymic cortical epithelium but rather a lack of sufficient T cell help for TD antigen
responses. This phenotype is identical to that of classicrather than medullary cells (Benoist and Mathis, 1989;
Jameson et al., 1995; Brocker et al., 1997). It is thus not MHC-II knockout mice (Kontgen et al., 1993; Cardell et
al., 1994; Grusby and Glimcher, 1995) and CIITA2/2 micesurprising that RFX52/2 mice are severely impaired in
the positive selection of CD4 SP thymocytes and conse- (Chang et al., 1996). It also reproduces the immunodefi-
ciency observed in patients known to have a mutationquently possess a profound deficiency in peripheral
CD41 T cells. The residual population of CD41 T cells in the RFX5 gene (Klein et al., 1993).
A puzzling difference with respect to the human dis-accounting for approximately 3% of total LN cells in the
RFX52/2 mice may be restricted to nonclassic MHC-I ease is that the CD41 T cell deficiency in RFX52/2 mice
is much more pronounced than the relatively modestmolecules, as has been described for conventional
MHC-II±deficient mice (Cardell et al., 1995). These T 2±4 fold reduction documented for MHC-II deficiency
Table 1. Residual Expression of MHC-II, 1i, and H-2M mRNAs in RFX52/2 Mice
Cell Type Ab Aa Eb Ii Ma Mb2 Mb1
Bulk GM-CSF BM culture 19 Ð Ð 73 92 45 Ð
CD11c1 BM DC 14 Ð Ð 61 76 28 Ð
Enriched splenic DC 67 22 30 108 67 47 62
Purified CD11c1MHC-II1 DC 20 60 80 ND ND ND ND
B2201 B cells 43 Ð 17 83 62 39 47
Total mesenteric LN cells 37 Ð Ð 96 66 49 70
Purified F4/801 peritoneal macrophages Ð Ð Ð ND ND ND ND
Values were derived from quantification of the gels shown in Figure 6 and are expressed as the percentage of transcripts present in the
homozygous RFX52/2 samples as compared to heterozygous RFX51/2 control samples. GAPDH mRNA levels were used to correct for sample
loading.
ND, not determined; Ð, no specific band visible above background.
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patients (Rieux-Laucat et al., 1993). One possibility is this is consistent with a similar pattern of expression in
the RFX52/2 mice. However, the loss of RFX5 has a morethat impairment of positive selection is less severe in
drastic effect than deletion of its X box target site. Inthe patients because mutations of the human regulatory
contrast to the RFX52/2 mice, the majority of B cellsfactors may permit low levels of MHC-II expression on
and macrophages were Ea1 in DX-Ea transgenic micecortical epithelial cells, although this was not observed
(van Ewijk et al., 1988).in the two patients from which thymic biopsies were
The ability of mature DC and activated B cells to tran-analyzed (Schuurman et al., 1985). Alternatively, theabil-
scribe MHC-II genes in the absence of RFX5 in miceity of selecting CD41 T cells restricted to nonclassic
contrasts with the phenotype of human cell lines, inMHC-I molecules (Cardell et al., 1995) may be more
which mutations of RFX5 completely abolish MHC-IIprevalent in the human than in mice. If the residual CD41
expression (Steimle et al., 1995). This may reflect a spe-T cells in MHC-II deficiency patients were indeed re-
cific difference in the requirement for RFX5. An alterna-stricted to nonclassic MHC-I molecules, this would ex-
tive explanation may be that a potential bypass of RFX5plain their apparent inability to proliferate in vitro in re-
also exists in humans but has escaped detection be-sponse to APC from healthy donors in the presence of
cause regulation of MHC-II gene expression in humansspecificprotein antigens (Mannhalter etal., 1986; Zegers
has been studied mainly in transformed cell lines. Sub-et al., 1986).
clones that spontaneously reexpressed MHC-II genes
have been described for Epstein Barr virus±transformed
B cell lines from some patients (Hadam et al., 1986) asCompartmentalization of MHC-II Expression
well as for the MHC-II regulatory mutant cell line 6.1.6in the Absence of RFX5
(Levine and Pious, 1984). These subclones didnot repre-Macrophages in RFX52/2 mice do not express measur-
sent true reversions of the genetic defect, since reex-able levels of MHC-II molecules and remain MHC-II2
pression was restricted to only a subset of MHC-II mole-following treatment with IFNg, which is the most potent
cules (see below). Instead, they could well reflect theinducer of MHC-II transcription in these cells (Boehm
existence of compensatory mechanisms that can, atet al., 1997). In contrast, the requirement for RFX5 is not
least in part, circumvent theabsence of the MHC-II regu-as strict in B cells and DC. Thus, a subpopulation of DC
latory factors affected by the mutations.can express MHC-II in the absence of RFX5Ðnamely,
The case of cell line 6.1.6 is of particular interest herethe interdigitating cells (IDC) in the T cell areas of spleen
because it has recently been shown toharbor a mutation(Figure 3) and LN (data not shown). This is corroborated
in RFXAP, which, like RFX5, is a subunit of the RFXby the identification of a CD11c1MHC-II1 cell population
complex (Durand et al., 1997). The phenotypic ªrever-in the spleen of RFX52/2 mice (Figure 4A) as well as the
sionº of 6.1.6 was found only in tetraploid cells, sug-thymus (data not shown) and by the demonstration that
gesting that the defect in RFXAP (or RFX) can be com-splenic DC retain high levels of MHC-II mRNA expres-
pensated for by a gene dosage effect (Levine and Pious,sion (Figure 6 and Table 1). However, in contrast to the
1984). Likewise, our results with RFX52/2 mice suggest
wild type, only a minority of CD11c1 DC are MHC-II1 in
that activation of DC and B cells might up-regulate ex-
the RFX52/2 mice. Specifically, the ability to bypass the
pression of a positive regulator that, above a critical
RFX5 defect seems to be restricted to the final stages
threshold level, substitutes for RFX5 (or RFX). To delin-
of DC maturation. This is supported by the observations eate possible redundancies in the function of the RFX
that only a few MHC-II1 DC are generated in GM-CSF± complex further, it will be informative to reevaluate the
supplemented cultures of RFX52/2 BM precursors (Fig- possibility of residual MHC-II expression in vivo in MHC-
ure 4B) and that the BM-derived DC purified from these II±deficient patients known to have mutations of the
cultures contain only low levels of I-Ab and I-Aa tran- RFX5 and RFXAP genes.
scripts (Figure 6 and Table 1). It is known that mainly
immature DC are generated in such GM-CSF±supple- Dyscoordinate Effect of the RFX5 Mutation on the
mented BM cultures (Inaba et al., 1992; Scheicher et al., Expression of Different Murine MHC-II Genes
1992). In the course of differentiation, DC thus appear In cells from RFX5-deficient patients, expression of all
to acquire a regulatory mechanism that permits MHC- MHC-II isotypes (HLA-DR, HLA-DP, and HLA-DQ) is
II expression in an RFX5-independent fashion. Similarly, abolished at the level of transcription (Steimle et al.,
resting B cells of RFX52/2 mice lack MHC-II but acquire 1995, and W.R., unpublished data). In contrast, mutation
the ability to express intermediate levels when they are of the murine RFX5 gene appears to affect different
activated in vitro (Figure 5B). Activation of B cells, like MHC-II genes to a different extent and in a cell type±
differentiation into mature DC, thus leads to the recruit- specific fashion (Figure 6 and Table 1). Whereas in mac-
ment of regulatory pathways that bypass the require- rophages the expression of all MHC-II genes is affected
ment for RFX5. equally, in many other cell populations, such as resting
The existence of RFX5±independent MHC-II expres- B cells, mesenteric LN cells, and the enriched splenic
sion is partially analogous to the previously observed DC cell preparation, the level of Aa and Eb mRNAs is
in vivo I-Ea expression driven from an MHC-II promoter reduced to a greater extent than that of Ab mRNA. In
harboring a deletion of the X box in transgenic DX-Ea purified and activated CD11c1MHC-II1 DC, on the other
mice (van Ewijk et al., 1988). I-Ea expression in DX- hand, Ab is the least abundant of the three mRNAs. The
Ea mice was absent from thymic cortex but present in elevated amounts of residual Aa and Eb transcripts in
thymic medulla and was also found on IDC in T cell the latter cell type suggest that there may be an RFX5-
areas of the spleen and on paracortical IDC in the LN. independent mechanism that specifically activates tran-
scription of these MHC-II genes in mature DC. SinceSince the X box is the target site recognized by RFX5,
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resting B cells already contain high levels of Ab mRNA, has a more stringent effect on MHC-II expression than
it is also tempting to speculate that MHC-II expression the deficiency in RFX5. In the CIITA2/2 mice, essentially
induced in activated B cells (Figure 5B) results mainly all cell types examined lack significant expression of
from up-regulation of the Aa mRNA. MHC-II molecules, apart from scattered MHC-II1 cells
Although not described previously, there may be a in the thymus (Figures 3, 4A, and 5B, and Chang et al.,
similar effect on different MHC-II genes in the CIITA 1996). This is in sharp contrast to the residual MHC-II
knockout mouse. In these mice, immunohistochemical expression observed in the RFX52/2 mice. The distinct
staining for MHC-II with the M5/114 monoclonal anti- effect of mutations in RFX5 and CIITA on MHC-II expres-
body gave weak signals in the T cell areas of splenic sion in mice was unexpected on the basis of the human
sections (Figure 3k). As discussed above (see Results) disease, since no characteristic features distinguishing
for RFX52/2 mice, this weak staining may indicate the RFX5-deficient patients from those with mutations in
presence of an excess of misfolded intracellular I-Ab CIITA have been described. This discrepancy could re-
chains in IDC. flect the existence of species-specific differences in the
A cell type±specific dyscoordinate expression of respective roles of the two MHC-II regulatory genes.
MHC-II genes has not been directly documented in pa- However, only relatively few patients from defined com-
tients with ªclassicº MHC-II deficiency, although there plementation groups have been studied in detail with
are indications for a similar phenomenon in humans. Of respect to residual MHC-II expression. Consequently,
interest in this respect are recent reports describing we suggest that a more precise and detailed phenotypic
an atypical and less severe form of MHC-II deficiency comparison of different patients is warranted and should
(Hauber et al., 1995; Douhan et al., 1996). In B cell lines be extended beyond the analysis of transformed cell
from these patients, HLA-DRb, HLA-DQb, and HLA-DPa lines to a variety of primary cell isolates or tissues.
genes are silent, while HLA-DRa, HLA-DQa, and HLA- Recently, a direct molecular interaction between
DPb genes are expressed. Although this dyscoordinate CIITA and RFX5 was detected in vitro (Scholl et al.,
expression is reminiscent of our observations inRFX52/2 1997), and the authors postulate that this interaction
mice, it must result from a different genetic defect be- is required for the recruitment of CIITA to the MHC-II
cause these patients do not belong to complementation promoter. This model is consistent with the strict re-
group C (Douhan et al., 1996). Dyscoordinate MHC-II
quirement for CIITA exemplified by the essential ab-
expression was also observed in the B cell line clone 13.
sence of surface MHC-II expression in CIITA2/2 mice,
Although clone 13 belongs to complementation group A
but it does not explain the differences between the
(in which CIITA is affected), it retains high levels of HLA-
RFX52/2 and CIITA2/2 phenotypes. These differences
DQ in the absence of DR and DP (Ono et al., 1991;
indicate that MHC-II genes can be activated by a CIITA-
Douhan et al., 1997). The expression of DQ in clone 13
dependent but RFX5-independent mechanism. Thehas been postulated to reflect the existence of an HLA-
RFX52/2 mice, in addition to providing an animal modelDQ±specific trans-acting factor that functions indepen-
for human MHC-II deficiency, should be helpful for thedently of CIITA (Douhan et al., 1997). Finally, the MHC-
elucidation of this and other intricacies of the control ofII1 variants derived from the patient cell lines (Hadam
MHC-II expression.et al., 1986) and from the 6.1.6 mutant (Levine and Pious,
1984) are characterized by reexpression of only certain
Experimental ProceduresMHC-II genesÐnamely, HLA-DP and HLA-DR, but not
HLA-DQ. With the findings reported here in mice, the
Generation of RFX5-Deficient Mice
differential expression of particular MHC-II genes in The mouse RFX5 gene was isolated from a 129/Sv genomic DNA
the patients with atypical deficiency, in clone 13, and library (a gift from M. Aguet). A 6 kb region spanning the gene was
in the phenotypic ªrevertantsº indicates that fine-tuning sequenced to determine the exon and intron structure. The gene
consists of nine coding exons (exons 1±9) preceded by four alterna-of the mechanisms coordinating transcription of MHC-
tively spliced 59 untranslated exons (Figure 1). Identity between theII genes may be more complex than previously thought.
human and mouse RFX5 genes was confirmed by (1) sequence
homology; (2) Southern blotting experiments; and (3) the ability ofDifferential Requirements for RFX5 the mouse RFX5 cDNA to complement the genetic defect in a human
and CIITA in the Transcriptional RFX5-deficient cell line (SJO) (Steimle et al., 1995).
Control of MHC-II Genes The targeting construct (Figure 1A) was prepared in pBluescript
Two genetic defects causing MHC-II deficiency in hu- (Stratagene) by standard recombinant DNA technology. It contains,
in order: (1) a unique SacII site to linearize the construct; (2) a 0.9mans, namely mutations in CIITA and RFX5, have now
kb EcoRI±StuI RFX5 fragment extending from exon 2 to the intronbeen reconstructed in mice. Similarities between these
between exons 3 and 4; (3) a loxP±flanked neomycin-resistancetwo mutant mouse lines include (1) impaired expression
gene under the control of a PGK promoter (PGK-neor); (4) a 1.4 kb
of MHC-II genes in the thymus and on professional APC; StuI±StuI RFX5 fragment extending from the intron between exons
(2) reduced levels of Ii and H-2M expression; (3) impaired 3 and 4 to the intron between exons 7 and 8; (4) an isolated loxP
positive selection; (4) a peripheral CD4 T cell deficiency; sequence; (5) a 5.0 kb StuI±BamHI RFX5 fragment extending from
and (5) an inability to mount TD immune responses. the intron between exons 7 and 8 to the 39 flanking region; and (6)
a polyoma enhancer±herpes simplex virus-1 thymidine kinase geneThese similarities confirm that the murine RFX5 and
(tk). Two HindIII sites and an XbaI site were introduced in the con-CIITA genes encode crucial regulatory factors control-
struct to facilitate Southern blotting analysis.ling multiple genes required for antigen presentation via
The linearized targeting vector was transfected into E14.1 embry-
MHC-II molecules. onic stem cells by electroporation, and G418 and gancyclovir dou-
On the other hand, there are clear phenotypic differ- ble-resistant clones were selected as described (Torres and KuÈ hn,
ences between these two mice, and these deserve spe- 1997). Homologous recombinants were screened first by PCR using
the external primerMRFX5C5 (59-CCGTGCAGAACAAAGTAGAG-39),cial emphasis. In general, disruption of the CIITA gene
Residual MHC II Expression in RFX5-Deficient Mice
153
which is located outside the short arm of homology of the targeting supernatant of X63 hybridoma transfected with a GM-CSF expres-
sion vector (Karasuyama and Melchers, 1988) (a gift from B. Stock-construct, and the internal primer PGKNEO1 (59-GCATGCTCCAGAC
TGCCTTG-39), which lies within the 59 end of the PGK-neor gene. inger, Medical Research Council, London) to drive differentiation
along the DC lineage.DC weresorted as CD11c1MHC-II1Gr12B2202Positive clones identified by PCR were confirmed by Southern blot
analysis after both an XbaI or HindIII digest, in combination with a cells.
Resident peritoneal macrophages were harvested by washing the59 external probe or an internal neor probe, respectively. Specifically,
the HindIII digest was indicative of a cointegration of the third loxP peritoneal cavity with 10 ml of medium. Cells were then cultured for
2 hr before nonadherent cells were removed, and the remainingsite. Two independently generated clones were expanded and in-
jected into C57Bl/6 blastocysts. Resulting chimeric mice were back- macrophages were incubated for 2 days in the presence or absence
of 100-200 U/ml recombinant mouse IFNg (Genzyme Diagnostics).crossed to the ªdeleterº strain characterized by germline expression
of the Cre recombinase (Schwenk et al., 1995). Germline transmis- For in vitro stimulation, splenocytes were cultured for 2 days with
10 U/ml recombinant murine IL-4 (Genzyme) and/or 10 mg/ml LPSsion was scored by coat color, and Cre-mediated deletion resulting
in a deleted RFX5 allele was identified by Southern blot analysis. (Sigma) in serum-free medium (AIM-V, Life Technologies).
Mice heterozygous for the mutation were intercrossed to produce
homozygous RFX52/2 offspring, which is routinely screened by PCR Immunohistochemistry
using the following primers to distinguish between the wild-type Eight-micrometer frozen tissue sections were air dried; fixed in ice-
(INT1/N4, 250 bp) and deleted (INT1/N8, 500 bp) alleles: MRFX5N4, cold acetone; blocked in phosphate-bufferedsaline containing 0.6%
59-CTCCTCATTGCTGAGCAGAC-39; MRFX5N8, 59-GGCTTTCTACG H2O2, 5% goat serum, and0.1% NaN3; and stained with digoxygenin-
ACATTCTTGGAC-39; and MRFX5INT1, 59-CACAACACTCATAACAA conjugated M5/114. The primary antibody was detected with anti-
ATGAG-39. digoxygenin peroxidase, followed by 3-amino-9-ethyl carbazole
RT-PCR analysis of RFX5 mRNA was done using primers (Sigma) to give a red precipitate. In the case of single stainings the
MRFX5C8 (59- GAATTCTGCAAGAAGTAC-39) and MRFX5N8 situ- sections were counterstained with hematoxylin. For double stain-
ated in exons 4 and 8, respectively. Wild-type and deleted alleles ings including anti-B220 staining, sections were blocked in addition
give rise to fragments of 715 and 191 bp, respectively. Sequence with 4% fetal calf serum in Tris-buffered saline and stained in paral-
of the deleted 191 bp fragment was established both by direct lel with biotinylated RA3-6B2. The primary antibody was developed
sequencing of the PCR product and by sequencing of five indepen- with streptavidin-alkaline phosphatase and alkaline phosphatase
dent subclones. substrate kit III/blue (Vector). Hematoxylin/eosin staining was per-
formed according to standard procedures using hematoxylin Gill#3
and eosin Y (Sigma).
Mice
All experiments were performed with 8- to 13-week-old mice. RNase Protection Analysis
RFX52/2 and RFX51/2 littermates were on a mixed Sv129/C57Bl/6 cDNA fragments for the murine MHC-II, Ii, H-2M, and GAPDH (glyc-
background, while Aa2/2, Ab2/2, and CIITA2/2 mice were C57Bl/6. eraldehyde 3-phosphate dehydrogenase) genes were amplified by
Ab2/2 mice were purchased from the Centre National de la Recher- RT-PCR from C57Bl/6 RNA and subcloned into pBluescript. Prepa-
che Scientifique (Orleans,France). CIITA2/2 mice (Chang et al., 1996) ration of 32P-labeled riboprobes and RNase protection experiments
were kindly provided by C.-H. Chang. Aa2/2 mice were from H. were performed as described (Steimle et al., 1994) using 1±5 mg of
Bluethmann (Basel, Switzerland). The animals were housed in spe- total RNA prepared with TRIzol (GIBCO BRL/Life Technologies).
cific pathogen±free conditions. Sizes in nucleotides (n) of the protected mRNA fragments and prim-
ers used for RT-PCR wereas follows: I-Aa: 121 n, 59-TGGGGTTGTCT
GTGGGCCTTG-39 and 59-CTCCCTTTCCAGGGTGTGAC-39; I-Ab:Cytofluorometric Analysis
226 n, 59-CCTCAACCACCACA-ACACT-39 and 59-TGGGGCTCTTCAFluorescence staining was performed as previously described (FoÈ r-
GGCTGGGAT-39; I-Eb: 155 n, 59-ACAGG-AATTGTGTCCACGGG-39ster and Rajewsky, 1987). Cells were analyzed on a FACScan (Bec-
and 59-TGTGCTTTCCACTCGACCGTGAC-39; Ii: 201 n, 59-CCTCCCAton Dickinson) or sorted on a FACStar (Becton Dickinson). The fol-
GAACCTGCAAC-39 and 59-GTCCAGACCTCGTGAGCAG-39; H-2Ma:lowing antibodies used in the experiments were purchased from
337 n, 59-GGACGAACTCTTCTCCTTCGACTTC-39 and 59-TGAGPharmingen: RM4-5 for CD4, 53-6.7 for CD8, AF6-88.5 for H-2Kb,
ATG-GATGTGGGGCTGGCTC-39; H-2Mb: 255 n for b2 and 120 n for25-9-17 for I-Abb, GL1 for CD86 (B7.2), HL3 for CD11c (N418), and Ly-
b1, 59-GCTCAT-GTGGAAAGCACG-39 and 59-CACATCCCAGAAAG6G for Gr1. Macrophages were identified by anti-F4/80 (MCA497F,
GTTGG-39; GAPDH, 109 n, 59-GGTGAAGGTCGGTGTGAA-39 andSerotec, England) or anti-Mac1 (M1/70) staining. M1/70 for Mac1
59-GTCAATGAAGGGGTCGTT-39.(Springer et al., 1979), RA3-6B2 for B220 (Coffman, 1982), and M5/
114 for MHC-II (Bhattacharya et al., 1981) were purified from hybrid-
Immunizationsoma supernatants in our laboratory.
Mice 8±12 weeks of age were injected intraperitoneally with either
100 mg of alumn-precipitated and g-irradiated NP15-CG (TD) or 10
mg NP27-Ficoll (TI). Serum was collected on days 0, 11, or 21 afterCell Preparation and Culture
primary immunization. Mice were boosted with 50 mg of NP-CGTo enrich for DC from splenic cell preparations, the organ was
after 3 weeks, and serum was collected 6 and 25 days later. NP-digested with collagenase (collagenase D, Boehringer Mannheim)
specific l1 and IgG3 (TI) or IgM and IgG1 (TD) immunoglobulinprior to preparation of a single-cell suspension, as has been de-
titers were measured by enzyme-linked immunosorbant assay asscribed elsewhere (Crowley et al., 1989). Next, total splenocytes
described (Roes and Rajewsky, 1993). The limit of detection for NP-were centrifuged over an OptiPrep density gradient (Nycomed, Nor-
specific antibodies was 0.08 mg/ml. Five mutant RFX52/2 and Ab2/2way) to recover a low-density cell fraction enriched for DC (z10%)
mice as well as five RFX51/2 littermates were used for each immuni-(Ruedl et al., 1996). DC were FACS-sorted after overnight culture of
zation.the low-density fraction to deplete contaminating macrophages by
plastic adherence. Alternatively, anti-CD11c (N418) MicroBeads
were used to positively enrich for DC from total splenocytes by Acknowledgments
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